Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC

A Randomized Controlled Study on the Effect of Adjuvant Anti-recurrence Treatment With Rapamycin on Early-stage HCC With Overexpression of ASPH After Radical Surgery.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02724332

Enrollment

300

Registered

2016-03-31

Start date

2012-11-30

Completion date

2015-12-31

Last updated

2016-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma, Rapamycin

Keywords

Aspartate beta hydroxylase, transcatheter arterial chemoembolization

Brief summary

To evaluate the clinical effect of rapamycin combined with TACE on early-stage HCC with overexpression of ASPH after radical surgery using randomized controlled study and provide a new anti-recurrence treatment for HCC patients after operation.

Interventions

DRUGRapamycin

2mg,po,bid

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. Via clinical diagnosis and confirm it is primary liver cancer 2. Pathological evidence of HCC 3. Estimate tumor can gain treatment of curing operation 4. No evidence for extrahepatic metestasis 5. liver function ：Child-Pugh A/B 6. BCLC stage：0/1；TNM stage：Ⅰ

Exclusion criteria

1. reject to attend； 2. impossible to come to our hospital for physical examination regularly. 3. cancer epitome、seed focus、lymph node or distant metastasis 4. Blood clotting function hindrance; 5, Patients with other diseases which may affect the treatment mentioned.

Design outcomes

Primary

Measure	Time frame
Overall Survival	3 years

Secondary

Measure	Time frame
Time to recurrence	3 years

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026